Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health, which recently closed a $7 million series A. Photo courtesy Koda Health.

Houston-based digital advance care planning company Koda Health has closed an oversubscribed $7 million series A funding round.

The round, led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center, will allow the company to scale operations and expand engineering, clinical strategy and customer success, according to a news release.

“This funding allows us to create more goals-of-care product lines, expand our national footprint, and bring goal-concordant care to millions more patients and families," Tatiana Fofanova, co-founder and CEO of Koda Health, said in the release.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, has seen major growth this year and said it now supports more than 1 million patients nationwide. The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April and with Epic Systems in July. Users of Epic's popular Mychart system and Guidehealth's clinically integrated networks can now document and share their care preferences, goals and advance directives for health systems using Koda Health's platform. It also has partnerships with Cigna, Privia and Memorial Hermann.

The company shared that the recent series A "marks a pivotal moment," as it has secured investments from influential leaders in the healthcare and venture capital space.

“Koda is the only company combining technology and service to deliver comprehensive solutions that help health plans, providers, and health systems scale goals-aligned care. With satisfied customers expanding their partnerships and policy shifts reinforcing the need for patient-centered care that also contains costs, we couldn’t be more excited to support the Koda team and their vision,” Sean Glass, managing partner at Evidenced, said in the release.

According to the company, a recent peer-reviewed study with Houston Methodist ACO showed that the platform can have a major impact on palliative care results and costs. The findings showed:

  • 79 percent reduction in terminal hospitalizations
  • 20 percent decrease in inpatient length of stay
  • 51 percent increase in hospice use among decedents
  • Nearly $9,000 in average savings per patient

“Patients long for clarity, families deserve peace of mind, and providers demand ease of use,” Dr. Desh Mohan, chief medical officer of Koda Health, added in the release. “At Koda, we make it possible to deliver all three — transforming Advance Care Planning into a compassionate, ongoing dialogue that honors patients and supports families every step of the way.”

Koda Health also closed an oversubscribed seed round for an undisclosed amount last year, with investments from AARP, Memorial Hermann Health System and the Texas Medical Center Venture Fund. Read more here.

Hampr Lite will give Houstonians a taste of what it's laundry service is like. Image courtesy of Hampr

Laundry startup unfolds new service in Houston

now in Hou

As Laurel Hess sat on a video call with a board member for her startup laundry service, a pile of laundry was peeking behind her.

“How can you have clothes piling up while owning a laundry business?” they asked.

Hess coolly replied, “Because laundry just doesn’t stop. It’s literally always there.”

Hampr is a hyper-local laundry and pick-up service that is connected and operated through an online app. The Lafayette-based company, which identified Houston as an early test market, links people who are in need of pick-up and wash laundry services with people in the local communities who are seeking work without leaving home.

A majority of the “washrs” who Hampr employs are stay-at-home parents and retirees who are looking for fast and steady work.

“People tend to think that we are this big national brand, but we are actually working with people in your market and you’re helping them by outsourcing your laundry,” says Hess, Hampr's foudner and CEO. “By using our service, you’re making a difference in the lives of the people who live in your community. It’s neighbors helping neighbors.”

The biggest challenge for the startup was finding the right network and getting investor interest. Hampr was part of the TechStars Austin Accelerator program and that helped expand their network and spring boarded the company on to a more national platform.

“Probably breaking out of the ecosystem was our biggest challenge that we faced,” Hess says. “Because there’s not a lot of peer-to-peer marketplace companies in Lafayette, Louisiana.”

Laurel Hess is the founder and CEO of Hampr. Photo courtesy of Hampr

Hess started the company in January 2020 and began pushing into new markets at the height of the pandemic. Hampr launched into its second market, Baton Rouge, the day that the shutdown happened.

“At first, we were a little nervous. The capital that we were raising had kind of gone away,” Hess says. “Investors were getting a little bit weary of what was going to happen.”

Two things then were true – Hampr didn’t have a lot of capital, but it also had demand in Houston – specifically The Woodlands/Kingwood area, as well as demand in DFW and New Orleans. Hess and her team then made the decision to launch in those markets, relying only on the people they knew in those areas and without any capital expenses.

“We had to do a lot with little – we didn’t have a whole lot of runway left,” she says.

Hess and her team began securing investors through their current networks in places like Houston. Then, a few months into the pandemic, they partnered with a health system to borrow the Hampr technology for PrestoHealth, a platform that delivers prescriptions. By harnessing the technology for another use, it became a way to earn more income for Hampr and they were able to launch into more new markets very quickly.

“The model itself is pretty solid and is deceptively simple,” Hess says. “Our COO in Houston grew the area without any capital investment. That’s how we were able to grow and survive the pandemic. And then once kids started back at school in August, things got crazy again and the laundry side started to pick up.”

The platform, which starts at $39 a year, is available Houston, Tomball, Conroe, The Woodlands, Kingwood as well as San Antonio, Austin, Dallas/Fort Worth, New Orleans, Baton Rouge, Lafayette, Jackson, Miss., Mobile, Alab., Jacksonville, Fla., Greenville/Spartanburg, South Carolina, Phoenix, Ariz., and Denver, Colo.

This week, the company rolled out a new service called Hampr Lite, where customers can pay a little more per load but can use it as an entry point into the platform without a full-year commitment. The service is available in some of its markets, including Houston.

“It’s kind of amazing because once you realize how much mental gymnastics that laundry takes from your weekend. You start to see what you can accomplish when you’re not worried about moving clothes from the washer to the dryer,” she says. “Then you realize there’s so much more room in your life for activities.”

Hampr gives stay-at-home parents or retirees an income option. Photo courtesy of Hampr

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”